文献速递前列腺增生与排尿功能障碍

Optilume BPH导管系统治疗良性前列腺增生随机对照试验的两年长期随访(PINNACLE研究)

Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE Study).
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-04-29

PINNACLE研究评估Optilume BPH导管系统治疗良性前列腺增生相关下尿路症状的两年结局,148例成人男性按2:1随机分配至Optilume BPH组(100例)或假手术组(48例),一年后仅Optilume BPH组继续随访。两年时67.5%(56/83,CI 56.3%,77.4%)为症状应答者,IPSS从23.4±5.5(n=100)改善至11.0±7.0(n=74),Qmax改善116.8%,BPH-II两年改善53.9%,无性功能影响,12个月后无器械或治疗相关严重不良事件。

要点

  • 两年时67.5%(56/83,CI 56.3%,77.4%)的Optilume BPH组参与者为症状应答者,定义为IPSS改善≥30%且未接受药物或手术再治疗。
  • IPSS从基线23.4±5.5(n=100)改善至两年时11.0±7.0(n=74),Qmax改善116.8%,BPH-II两年改善53.9%。
  • Optilume BPH组最常见不良事件为血尿和尿路感染,术后12个月后无器械或治疗相关严重不良事件,性功能无影响。

核心结论

  • PINNACLE研究中,接受Optilume BPH导管系统治疗的参与者在两年时表现出持续且持久的结果,证实了耐受性、安全性和持久有效性,提供与更具侵入性疗法相当的结果,同时保留微创疗法的优势。

研究设计与样本

  • 148例有症状的良性前列腺增生成人男性入组,按2:1随机分配至Optilume BPH组(100例)或假手术组(48例),一年后随访仅限Optilume BPH组。

主要发现

  • 两年时67.5%(56/83,CI 56.3%,77.4%)的Optilume BPH组参与者为症状应答者,定义为IPSS改善≥30%且未接受药物或手术再治疗。
  • IPSS从23.4±5.5(n=100)显著改善至11.0±7.0(n=74)。
  • Qmax改善116.8%(8.9±2.2,n=97至19.0±16.3,n=65),PVR轻微降低(83.7±70.3,n=99至65.9±74.5,n=65)。
  • BPH-II从7.0±2.9(n=98)改善至1年时2.3±2.5(n=89),两年时保持2.3±2.9(n=74),改善53.9%;IPSS QoL从基线4.6±1.3(n=100)改善至2.2±1.5(n=74)。
  • Optilume BPH组最常见不良事件为血尿和尿路感染,术后12个月后无器械或治疗相关严重不良事件,性功能无影响。

局限性

  • 一年后随访仅限接受Optilume BPH治疗的参与者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patient outcomes were assessed 2 years after treatment with the Optilume BPH Catheter System, a minimally invasive surgical therapy for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). METHODS: One-hundred forty-eight adult males with symptomatic BPH were enrolled and randomized in a 2:1 fashion to Optilume BPH or Sham (100 Optilume BPH; 48 Sham). Long-term measures include International Prostate Symptom Score (IPSS), peak urinary flow rate (Qmax), Post-Void Residual Urine (PVR), quality of life measures and sexual function. Follow-up beyond one year was limited to those treated with Optilume BPH. RESULTS: At 2 years, 67.5% (56/83 CI 56.3%, 77.4%) of participants in the Optilume BPH arm were symptomatic responders as defined by ≥30% improvement in IPSS without medical or surgical retreatment. IPSS significantly improved from 23.4 ± 5.5 (n = 100) to 11.0 ± 7.0 (n = 74). Qmax improved by 116.8.% (8.9 ± 2.2 (n = 97) to 19.0 ± 16.3 (n = 65)), while PVR showed a slight reduction (83.7 ± 70.3 (n = 99) to 65.9 ± 74.5 (n = 65)). Improvement in uroflowmetry measures was consistent across all prostate volumes. BPH-II improved from 7.0 ± 2.9 (n = 98) to 2.3 ± 2.5 at 1 year (n = 89) and remained consistent at 2.3 ± 2.9 at the 2-years (n = 74), representing a 53.9% improvement. IPSS QoL also improved from 4.6 ± 1.3 (n = 100) at baseline to 2.2 ± 1.5 (n = 74). The most common adverse events reported in the Optilume BPH arm were hematuria and urinary tract infection (UTI). No device and/or treatment related serious adverse events were reported occurring beyond 12 months post-procedure. There was no impact to sexual function. CONCLUSIONS: In the PINNACLE study, participants treated with the Optilume BPH Catheter System demonstrated continued and durable results at 2 years, affirming tolerability, safety, and the enduring effectiveness. The Optilume BPH Catheter System provides lasting results that are comparable to the more invasive therapies, while preserving the advantages with being a minimally invasive therapy. REGISTRATION: ClinicalTrials.gov NCT04131907.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Kaplan SA, Moss JL, Freedman SJ, et al. Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE Study). Prostate Cancer Prostatic Dis. 2024. PMID: 38684918. doi:10.1038/s41391-024-00833-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。